Evidence map›Paper›PMID 42053471›Full record

ArticleJournal of clinical pharmacology2026

Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir.

Jing Niu, Haeyoung Zhang, John Ling, Sharline Madera, Nerissa Kwok, Steve West, Diane Longo, Gillian Gillespie, Cyril Llamoso, Dhananjay D Marathe

Abstract readClinical Trial, Phase I
In one paragraph

Article in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing NiuGilead Sciences, Inc., Foster City, CA, USA.
Haeyoung ZhangGilead Sciences, Inc., Foster City, CA, USA.
John LingGilead Sciences, Inc., Foster City, CA, USA.
Sharline MaderaGilead Sciences, Inc., Foster City, CA, USA.
Nerissa KwokGilead Sciences, Inc., Foster City, CA, USA.
Steve WestGilead Sciences, Inc., Foster City, CA, USA.
Diane LongoMerck & Co., Inc., Rahway, NJ, USA.
Gillian GillespieMerck & Co., Inc., Rahway, NJ, USA.
Cyril LlamosoMerck & Co., Inc., Rahway, NJ, USA.
Dhananjay D MaratheGilead Sciences, Inc., Foster City, CA, USA.ORCID 0000-0003-0238-2252

Funding

Gilead Sciences, Inc.Merck & Co., IncMerck Sharp & Dohme LLC
6 · The paper itself

Abstract

Long-acting oral HIV-1 treatments can potentially reduce pill burden, treatment fatigue, suboptimal adherence, and treatment failure. A combination of islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a capsid inhibitor, is being investigated as a weekly oral HIV-1 treatment. In this open-label, phase 1 study of 93 people without HIV, we investigated pharmacokinetics to evaluate the oral relative bioavailability and safety of a fixed-dose combination (FDC) tablet containing islatravir 2 mg and lenacapavir 300 mg, compared with respective single-agent islatravir 2 mg and lenacapavir 300 mg coadministration under fasted conditions, as well as the food effect for FDC administration. Islatravir pharmacokinetics showed similar mean area under the time-concentration curve extrapolated to infinity (AUC

Indexed as

Anti-HIV AgentsFood-Drug InteractionsQuinolonesAcetamidesAdministration, OralAdultArea Under CurveBiological AvailabilityDeoxyadenosinesDrug CombinationsFemaleHumansIndazolesMaleMiddle AgedTabletsAcetamidesAnti-HIV AgentsDeoxyadenosinesDrug CombinationsIndazolesislatravirlenacapavirQuinolonesTabletsHIVislatravirlenacapavirpharmacokinetics

Identifiers

PMID42053471
PMCPMC13127353

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.